Epidemiology of zoonotic hepatitis E: a community-based surveillance study in a rural population in China

Feng-Cai Zhu, Shou-Jie Huang, Ting Wu, Xue-Feng Zhang, Zhong-Ze Wang, Xing Ai, Qiang Yan, Chang-Lin Yang, Jia-Ping Cai, Han-Min Jiang, Yi-Jun Wang, Mun-Hon Ng, Jun Zhang, Ning-Shao Xia, Feng-Cai Zhu, Shou-Jie Huang, Ting Wu, Xue-Feng Zhang, Zhong-Ze Wang, Xing Ai, Qiang Yan, Chang-Lin Yang, Jia-Ping Cai, Han-Min Jiang, Yi-Jun Wang, Mun-Hon Ng, Jun Zhang, Ning-Shao Xia

Abstract

Background: Hepatitis E is caused by two viral genotype groups: human types and zoonotic types. Current understanding of the epidemiology of the zoonotic hepatitis E disease is founded largely on hospital-based studies.

Methods: The epidemiology of hepatitis E was investigated in a community-based surveillance study conducted over one year in a rural city in eastern China with a registered population of 400,162.

Results: The seroprevalence of hepatitis E in the cohort was 38%. The incidence of hepatitis E was 2.8/10,000 person-years. Totally 93.5% of the infections were attributed to genotype 4 and the rest, to genotype 1. Hepatitis E accounted for 28.4% (102/359) of the acute hepatitis cases and 68.9% (102/148) of the acute viral hepatitis cases in this area of China. The disease occurred sporadically with a higher prevalence during the cold season and in men, with the male-to-female ratio of 3∶1. Additionally, the incidence of hepatitis E increased with age. Hepatitis B virus carriers have an increased risk of contracting hepatitis E than the general population (OR = 2.5, 95%CI 1.5-4.2). Pre-existing immunity to hepatitis E lowered the risk (relative risk = 0.34, 95% CI 0.21-0.55) and reduced the severity of the disease.

Conclusions: Hepatitis E in the rural population of China is essentially that of a zoonosis due to the genotype 4 virus, the epidemiology of which is similar to that due to the other zoonotic genotype 3 virus.

Conflict of interest statement

Competing Interests: The authors have declared that no competing interests exist.

Figures

Figure 1. Sentinel surveillance of acute hepatitis…
Figure 1. Sentinel surveillance of acute hepatitis in rural community.
A sentinel surveillance study of acute hepatitis was conducted over 12 months between 2006 and 2007 in 10 rural townships with a combined population of 400,162. A total of 1,428 suspected cases presented within 21 days of onset of symptoms to local healthcare centers or hospitals during this period and 359 of which were diagnosed with acute hepatitis, having elevated serum ALT levels of 2.5 to 116.7 ULN (Upper Limit of Normal). Paired acute and convalescent serum samples were obtained from 271 of the acute hepatitis patients and single acute samples, from 88 patients for differential diagnosis of acute hepatitis caused by hepatitis viruses.
Figure 2. Seasonal distribution of hepatitis E.
Figure 2. Seasonal distribution of hepatitis E.
Hepatitis E cases detected as described in Table 1 occurred sporadically throughout 12 months with ≤2 cases in any one village over any 30 days period. Most (70.6%, 72/102) of the cases occurred in the months of October to March.
Figure 3. Age and gender distribution of…
Figure 3. Age and gender distribution of hepatitis E.
Noted virtually all the hepatitis E cases (see Table 1) occurred after age 20 years, most of which, among men (shaded block) and few among women (open block). Incidence of the infection (line) increases with age, reaching peak levels after 60 years of age.
Figure 4. Acute marker profiles of hepatitis…
Figure 4. Acute marker profiles of hepatitis E.
Of the 102 hepatitis E cases in the present series (see Table 1), 11 (cases 92 to 102) were detected according to occurrence of IgM anti-HEV and HEV RNA in single acute serum samples and the others (cases 1 to 91), according to occurrence of these markers and also ≥4 fold rise of IgG anti-HEV levels in paired serum samples. Additional low avidity IgG anti-HEV test was done for some of the samples, including those tested positive for rising IgG anti-HEV (cases 1 to 8) alone and those positive for IgM anti-HEV alone (cases 88 to 91 and cases 99 to 102). (+) denotes a positive finding and (-), for a negative finding, for the acute marker in individual samples and blank space denotes test not performed. The resulting acute marker profiles of cases 10 to 102 featured a positive IgM anti-HEV, and variously accompanied low avidity IgG or the other acute markers, are consistent with responses to primary infection by hitherto immunologically naïve subjects. The profiles of cases 1 to 9, featuring rising IgG and a negative finding for the other markers, except one (case 9), who was also tested positive for HEV RNA, are consistent with anamnestic responses by immune subjects to reinfection. HEV: hepatitis E virus.

References

    1. Purcell RH, Emerson SU (2005) Prevention. In: Thomas HC, Lemon S, Zuckerman AJ, editors. Viral hepatitis, 3rd edn. Malden, MA Blackwell Publishing. pp. 635–645.
    1. Purcell RH, Emerson SU (2008) Hepatitis E: an emerging awareness of an old disease. J Hepatol 48: 494–503.
    1. Dalton HR, Bendall RP, Keane FE, Tedder RS, Ijaz S (2009) Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 361: 1025–1027.
    1. Teshale EH, Howard CM, Grytdal SP, Handzel TR, Barry V, et al. (2010) Hepatitis E epidemic, Uganda. Emerg Infect Dis 16: 126–129.
    1. Teshale EH, Hu DJ, Holmberg SD (2010) The two faces of hepatitis E virus. Clin Infect Dis 51: 328–334.
    1. Dalton HR, Hazeldine S, Banks M, Ijaz S, Bendall R (2007) Locally acquired hepatitis E in chronic liver disease. Lancet 369: 1260.
    1. Kumar Acharya S, Kumar Sharma P, Singh R, Kumar Mohanty S, Madan K, et al. (2007) Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death. J Hepatol 46: 387–394.
    1. Lu L, Li C, Hagedorn CH (2006) Phylogenetic analysis of global hepatitis E virus sequences: genetic diversity, subtypes and zoonosis. Rev Med Virol 16: 5–36.
    1. Dalton HR, Bendall R, Ijaz S, Banks M (2008) Hepatitis E: an emerging infection in developed countries. Lancet Infect Dis 8: 698–709.
    1. Zhuang H, Zhu WF, Li F (1999) Studies on hepatitis E. . Chin Med Sci J 14: 47–50.
    1. Cooper K, Huang FF, Batista L, Rayo CD, Bezanilla JC, et al. (2005) Identification of genotype 3 hepatitis E virus (HEV) in serum and fecal samples from pigs in Thailand and Mexico, where genotype 1 and 2 HEV strains are prevalent in the respective human populations. J Clin Microbiol 43: 1684–1688.
    1. Corwin AL, Khiem HB, Clayson ET, Pham KS, Vo TT, et al. (1996) A waterborne outbreak of hepatitis E virus transmission in southwestern Vietnam. Am J Trop Med Hyg 54: 559–562.
    1. Khuroo MS (1980) Study of an epidemic of non-A, non-B hepatitis. Possibility of another human hepatitis virus distinct from post-transfusion non-A, non-B type. Am J Med 68: 818–824.
    1. Naik SR, Aggarwal R, Salunke PN, Mehrotra NN (1992) A large waterborne viral hepatitis E epidemic in Kanpur, India. Bull World Health Organ 70: 597–604.
    1. Velazquez O, Stetler HC, Avila C, Ornelas G, Alvarez C, et al. (1990) Epidemic transmission of enterically transmitted non-A, non-B hepatitis in Mexico, 1986–1987. JAMA 263: 3281–3285.
    1. Hoofnagle JH, Nelson KE, Purcell RH (2012) Hepatitis E. N Engl J Med 367: 1237–1244.
    1. Zheng Y, Ge S, Zhang J, Guo Q, Ng MH, et al. (2006) Swine as a Principal Reservoir of Hepatitis E Virus that Infects Humans in Eastern China. J Infect Dis 193: 1643–1649.
    1. Ijaz S, Arnold E, Banks M, Bendall RP, Cramp ME, et al. (2005) Non-travel-associated hepatitis E in England and Wales: demographic, clinical, and molecular epidemiological characteristics. J Infect Dis 192: 1166–1172.
    1. Mansuy JM, Abravanel F, Miedouge M, Mengelle C, Merviel C, et al. (2009) Acute hepatitis E in south-west France over a 5-year period. J Clin Virol 44: 74–77.
    1. Said B, Ijaz S, Kafatos G, Booth L, Thomas HL, et al. (2009) Hepatitis E outbreak on cruise ship. Emerg Infect Dis 15: 1738–1744.
    1. Dalton HR, Fellows HJ, Gane EJ, Wong P, Gerred S, et al. (2007) Hepatitis E in new zealand. J Gastroenterol Hepatol 22: 1236–1240.
    1. Meng XJ, Wiseman B, Elvinger F, Guenette DK, Toth TE, et al. (2002) Prevalence of antibodies to hepatitis E virus in veterinarians working with swine and in normal blood donors in the United States and other countries. J Clin Microbiol 40: 117–122.
    1. Abe K, Li TC, Ding X, Win KM, Shrestha PK, et al. (2006) International collaborative survey on epidemiology of hepatitis E virus in 11 countries. Southeast Asian J Trop Med Public Health 37: 90–95.
    1. Kuniholm MH, Purcell RH, McQuillan GM, Engle RE, Wasley A, et al. (2009) Epidemiology of Hepatitis E Virus in the United States: Results from the Third National Health and Nutrition Examination Survey, 1988–1994. J Infect Dis 200: 48–56.
    1. Mansuy JM, Bendall R, Legrand-Abravanel F, Saune K, Miedouge M, et al. (2011) Hepatitis E virus antibodies in blood donors, France. Emerg Infect Dis 17: 2309–2312.
    1. Boutrouille A, Bakkali-Kassimi L, Cruciere C, Pavio N (2007) Prevalence of anti-hepatitis E virus antibodies in French blood donors. J Clin Microbiol 45: 2009–2010.
    1. Buti M, Dominguez A, Plans P, Jardi R, Schaper M, et al. (2006) Community-based seroepidemiological survey of hepatitis E virus infection in Catalonia, Spain. Clin Vaccine Immunol 13: 1328–1332.
    1. Ijaz S, Vyse AJ, Morgan D, Pebody RG, Tedder RS, et al. (2009) Indigenous hepatitis E virus infection in England: more common than it seems. J Clin Virol 44: 272–276.
    1. Taniguchi M, Kim SR, Mishiro S, Takahashi K, Shin MH, et al. (2009) Epidemiology of hepatitis E in Northeastern China, South Korea and Japan. J Infect 58: 232–237.
    1. Christensen PB, Engle RE, Hjort C, Homburg KM, Vach W, et al. (2008) Time trend of the prevalence of hepatitis E antibodies among farmers and blood donors: a potential zoonosis in Denmark. Clin Infect Dis 47: 1026–1031.
    1. Zhu FC, Zhang J, Zhang XF, Zhou C, Wang ZZ, et al. (2010) Efficacy and safety of a recombinant hepatitis E vaccine in healthy adults: a large-scale, randomised, double-blind placebo-controlled, phase 3 trial. Lancet 376: 895–902.
    1. Huang S, Zhang X, Jiang H, Yan Q, Ai X, et al. (2010) Profile of acute infectious markers in sporadic hepatitis E. PLoS One 5: e13560.
    1. Li RC, Ge SX, Li YP, Zheng YJ, Nong Y, et al. (2006) Seroprevalence of hepatitis E virus infection, rural southern People's Republic of China. Emerg Infect Dis 12: 1682–1688.
    1. Zhang J, Ge SX, Huang GY, Li SW, He ZQ, et al. (2003) Evaluation of antibody-based and nucleic acid-based assays for diagnosis of hepatitis E virus infection in a rhesus monkey model. J Med Virol 71: 518–526.
    1. Zhang J, Zhang XF, Zhou C, Wang ZZ, Huang SJ, et al.. (2013) Protection against hepatitis E virus infection by naturally acquired and vaccine-induced immunity. Clin Microbiol Infect. [Epub ahead of print]
    1. Wedemeyer H, Rybczynska J, Pischke S, Krawczynski K (2013) Immunopathogenesis of hepatitis E virus infection. Semin Liver Dis 33: 71–78.
    1. Seriwatana J, Shrestha MP, Scott RM, Tsarev SA, Vaughn DW, et al. (2002) Clinical and epidemiological relevance of quantitating hepatitis E virus-specific immunoglobulin M. Clin Diagn Lab Immunol 9: 1072–1078.
    1. Myint KS, Endy TP, Gibbons RV, Laras K, Mammen MP Jr, et al. (2006) Evaluation of diagnostic assays for hepatitis E virus in outbreak settings. J Clin Microbiol 44: 1581–1583.
    1. Herremans M, Bakker J, Duizer E, Vennema H, Koopmans MP (2007) Use of serological assays for diagnosis of hepatitis E virus genotype 1 and 3 infections in a setting of low endemicity. Clin Vaccine Immunol 14: 562–568.
    1. Legrand-Abravanel F, Thevenet I, Mansuy JM, Saune K, Vischi F, et al. (2009) Good performance of immunoglobulin M assays in diagnosing genotype 3 hepatitis E virus infections. Clin Vaccine Immunol 16: 772–774.
    1. Chen HY, Lu Y, Howard T, Anderson D, Fong PY, et al. (2005) Comparison of a new immunochromatographic test to enzyme-linked immunosorbent assay for rapid detection of immunoglobulin m antibodies to hepatitis e virus in human sera. Clin Diagn Lab Immunol 12: 593–598.
    1. Myint KS, Guan M, Chen HY, Lu Y, Anderson D, et al. (2005) Evaluation of a new rapid immunochromatographic assay for serodiagnosis of acute hepatitis E infection. Am J Trop Med Hyg 73: 942–946.
    1. Kamar N, Selves J, Mansuy JM, Ouezzani L, Peron JM, et al. (2008) Hepatitis E virus and chronic hepatitis in organ-transplant recipients. N Engl J Med 358: 811–817.

Source: PubMed

3
S'abonner